Efficacy and safety of fumaric acid esters in the long‐term treatment of psoriasis–a retrospective study (FUTURE)
K Reich, D Thaci, U Mrowietz, A Kamps… - JDDG: Journal der …, 2009 - Wiley Online Library
K Reich, D Thaci, U Mrowietz, A Kamps, M Neureither, T Luger
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009•Wiley Online LibraryBackground: This study collected data on the safety and efficacy of fumaric acid esters (FAE;
Fumaderm®) in the long‐term treatment of psoriasis. Patients and Methods: Patients were
included at 163 dermatological centers if they either had been treated continuously with FAE
for at least 24 months, or for 36 months with interruptions of no longer than 6 months. Data
were reported from baseline, after 3, 6, 12, 24, and 36 or more months of therapy. Safety
parameters were monitored and the severity of skin symptoms was assessed by “Physician's …
Fumaderm®) in the long‐term treatment of psoriasis. Patients and Methods: Patients were
included at 163 dermatological centers if they either had been treated continuously with FAE
for at least 24 months, or for 36 months with interruptions of no longer than 6 months. Data
were reported from baseline, after 3, 6, 12, 24, and 36 or more months of therapy. Safety
parameters were monitored and the severity of skin symptoms was assessed by “Physician's …
Summary
Background: This study collected data on the safety and efficacy of fumaric acid esters (FAE; Fumaderm®) in the long‐term treatment of psoriasis.
Patients and Methods: Patients were included at 163 dermatological centers if they either had been treated continuously with FAE for at least 24 months, or for 36 months with interruptions of no longer than 6 months. Data were reported from baseline, after 3, 6, 12, 24, and 36 or more months of therapy. Safety parameters were monitored and the severity of skin symptoms was assessed by “Physician's Global Assessment” (PGA) and “Psoriasis Area and Severity Index” (PASI).
Results: 984 patients were included with a mean duration of 44 months of continuous treatment. The percentage of patients documented as markedly improved or clear was 67 % after six months, 78 % after 24 months, and 82 % after 36 months of therapy. Improvement was similar in patients with moderate and severe disease. Changes of laboratory parameters were usually insignificant and did not require a modification of FAE treatment in more than 90 % of the cases.
Conclusions: In the long‐term treatment of patients with moderate and severe psoriasis FAE show a good and sustained clinical efficacy combined with a favorable safety profile.
Wiley Online Library